Linked Life Data

18073016

Source:http://linkedlifedata.com/resource/pubmed/id/18073016

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18073016rdf:typepubmed:Citationlld:pubmed
pubmed-article:18073016lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C0205466lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C0035379lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C0017431lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C1963724lld:lifeskim
pubmed-article:18073016lifeskim:mentionsumls-concept:C1512900lld:lifeskim
pubmed-article:18073016pubmed:issue12lld:pubmed
pubmed-article:18073016pubmed:dateCreated2007-12-12lld:pubmed
pubmed-article:18073016pubmed:abstractTextNon-nucleoside reverse transcriptase inhibitors (NNRTIs) have a longer half-life than nucleoside reverse transcriptase inhibitor (NRTIs). Simultaneous interruption of all drugs exposes the patients to NNRTI monotherapy. This study evaluated HIV-1 genotype after treatment interruption (TI) of NNRTI-based antiretroviral therapy (ART) and virological response after resumption of the same ART regimen. A prospective study was conducted in HIV-1-infected patients who enrolled into a CD4-guided TI study. All patients continued dual NRTIs for a further 7-10 days at NNRTI TI. HIV-1 genotypic assay was performed prior to resumption of the same ART regimen. Forty-three patients required ART resumption after TI from NNRTI-based regimens. Mean age was 42.7 years; 44% were men. Median CD4 and HIV-1 RNA at the time of ART resumption were 178 cell/mm(3) and 5.78 log copies/mL, respectively. HIV-1 genotype revealed no mutations contributed to NRTI or NNRTI resistance. Of all, 56% and 100% patients achieved undetectable HIV-1 RNA at three and six months, respectively. Median CD4 were 386 and 419 cells/mm(3) at the corresponding periods. In conclusion, continuation of dual NRTIs for 7-10 days after TI of NNRTI-based regimens can minimize the risk of acquired NNRTI resistance. With this strategy, the same regimen can be used for resumption and also yield good virological and immunological outcomes.lld:pubmed
pubmed-article:18073016pubmed:languageenglld:pubmed
pubmed-article:18073016pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18073016pubmed:citationSubsetIMlld:pubmed
pubmed-article:18073016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18073016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18073016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18073016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18073016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18073016pubmed:statusMEDLINElld:pubmed
pubmed-article:18073016pubmed:monthDeclld:pubmed
pubmed-article:18073016pubmed:issn0956-4624lld:pubmed
pubmed-article:18073016pubmed:authorpubmed-author:Apisarnthanar...lld:pubmed
pubmed-article:18073016pubmed:authorpubmed-author:Sungkanuparph...lld:pubmed
pubmed-article:18073016pubmed:authorpubmed-author:Kiertiburanak...lld:pubmed
pubmed-article:18073016pubmed:authorpubmed-author:MalathumKumth...lld:pubmed
pubmed-article:18073016pubmed:authorpubmed-author:Sathapatayavo...lld:pubmed
pubmed-article:18073016pubmed:issnTypePrintlld:pubmed
pubmed-article:18073016pubmed:volume18lld:pubmed
pubmed-article:18073016pubmed:ownerNLMlld:pubmed
pubmed-article:18073016pubmed:authorsCompleteYlld:pubmed
pubmed-article:18073016pubmed:pagination832-4lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:meshHeadingpubmed-meshheading:18073016...lld:pubmed
pubmed-article:18073016pubmed:year2007lld:pubmed
pubmed-article:18073016pubmed:articleTitleHIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.lld:pubmed
pubmed-article:18073016pubmed:affiliationFaculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. ssungkanuparph@yahoo.comlld:pubmed
pubmed-article:18073016pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18073016pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:18073016pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18073016lld:pubmed